Skip to main content
. 2021 Sep 29;22(19):10541. doi: 10.3390/ijms221910541

Table 1.

Anthropometric and clinical characteristics of the study patients.

Ob (n = 24) Ob-NAFLD (n = 24) p-Value
Age (years) a 44.88 ± 10.87 45.75 ± 8.94 0.762
BMI (kg/m2) a 44.00 ± 5.32 44.41 ± 4.75 0.778
Waist (cm) 118.5 (111.3–129.3) 119.5 (116.3–125.8) 0.900
Hip (cm) 137.7 ± 9.49 133.2 ± 9.145 0.222
Waist-to-hip ratio 0.88 ± 0.08 0.91 ± 0.05 0.246
CUN-BAE Index 54.2 (52.3–55.6) 54.5 (52.7–56.5) 0.660
HTN 5 (20.83%) 9 (37.50%) 0.341 b
TG (mg/dL) 189.0 ± 33.02 200.0 ± 37.96 0.027
Total cholesterol (mg/dL) 193.82 ± 24.44 202.55 ± 36.2 0.289
HDL (mg/dL) 53.75 ± 8.65 45.58 ± 7.88 0.001
LDL (mg/dL) 116.3 ± 25.08 125.2 ± 29.96 0.277
FPG (mg/dL) 90.5 (88.5–101.0) 99.0 (90.5–105.8) 0.264
T2D a 5 (20.83%) 5 (20.83%) >0.999 b
HbA1c (%) 5.5 (5.3–5.7) 5.6 (5.3–6.1) 0.493
AST (IU/L) 20.5 (16.7–23.0) 21.0 (17.0–27.7) 0.454
ALT (IU/L) 21.0 (15.0–25.0) 22.0 (17.2–40.5) 0.159
GGT (IU/L) 19.0 (14.0–31.0) 24.0 (18.2–38.7) 0.349
AST:ALT ratio 1.0 (0.8–1.1) 0.8 (0.6–1.0) 0.158
Platelets (×109/L) 268 (241–306) 294 (248–382) 0.125
CRP (mg/dL) 0.48 (0.34–1.21) 0.95 (0.38–1.81) 0.230
FIB-4 Score 0.71 (0.51–0.86) 0.69 (0.44–0.91) 0.778
APRI Score 0.18 (0.14–0.22) 0.19 (0.14–0.21) 0.813

Data are presented mean ± SD, median (IQR) or n (%). NAFLD, nonalcoholic fatty liver disease; BMI, body mass index; CUN-BAE Index, body adiposity estimator; HTN, hypertension; TG, serum triglyceride level; HDL, serum high-density lipoprotein cholesterol level; LDL, serum low density lipoprotein cholesterol level; FPG, fasting plasma glucose; T2D, type 2 diabetes; HbA1c, glycosylated haemoglobin; AST, serum aspartate aminotransferase level; ALT, serum alanine aminotransferase level; GGT, gamma-glutamyl transferase; CRP, C-reactive protein; FIB-4, index for liver fibrosis; APRI, AST to platelet ratio index. Welch’s t-test or Mann-Whitney test were applied except otherwise stated. a Matching variable. b Fisher’s exact test.